Carbonic Anhydrases (Carbonic Anhydrase)

A family of zinc-containing enzymes that catalyze the reversible hydration of carbon dioxide. They play an important role in the transport of CARBON DIOXIDE from the tissues to the LUNG. EC 4.2.1.1.

Also Known As:

Networked: 1812 relevant articles (36 outcomes, 219 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Supuran, Claudiu T: 232 articles (12/2015 - 02/2003)
2.	Scozzafava, Andrea: 93 articles (04/2015 - 03/2003)
3.	Vullo, Daniela: 73 articles (10/2015 - 03/2003)
4.	Pastorekova, Silvia: 51 articles (07/2015 - 03/2003)
5.	Pastorek, Jaromir: 48 articles (04/2015 - 02/2003)
6.	Harris, Adrian L: 40 articles (10/2015 - 08/2002)
7.	Winum, Jean-Yves: 39 articles (09/2015 - 05/2003)
8.	Innocenti, Alessio: 38 articles (09/2012 - 10/2004)
9.	Parkkila, Seppo: 34 articles (05/2015 - 12/2002)
10.	Oosterwijk, Egbert: 30 articles (08/2015 - 09/2003)

Related Diseases

1.	Glaucoma 07/01/2007 - "Due to characteristic physicochemical properties of sulphonamide (Inhibition of Carbonic Anhydrase), they are clinically effective against glaucoma. " 01/01/2014 - "Inhibition of carbonic anhydrase (CA, EC 4.2.1.1) has pharmacologic applications in the treatment of glaucoma, a disease affecting a large number of people and characterized by an elevated intraocular pressure (IOP). " 07/01/2008 - "In all patients, the IOP increase was sustained across several visits, requiring control with topical glaucoma therapy, and in two cases the addition of a systemic carbonic anhydrase inhibitor. " 10/01/2007 - "Inhibition of carbonic anhydrase in the eye is an important treatment modality for reducing the intraocular pressure in glaucoma. " 10/07/2004 - "Sulfonamide carbonic anhydrase (CA) inhibitors are widely employed in the diagnosis and treatment of diverse diseases such as glaucoma and different neuromuscular disorders. "
2.	Open-Angle Glaucoma (Glaucoma, Open Angle) 12/01/1999 - "[Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma]." 07/01/1998 - "Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma." 01/01/1998 - "Clinical use of a topical carbonic anhydrase inhibitor in patients affected by chronic simple glaucoma." 10/01/1991 - "For several decades a tantalizing goal for the treatment of primary open-angle glaucoma has been the development of a topically active carbonic anhydrase inhibitor. " 01/15/1989 - "We tested the effect on intraocular pressure of three commonly used oral carbonic anhydrase inhibitor preparations in a controlled, randomized, comparative study on patients with primary open-angle glaucoma. "
3.	Macular Edema 01/01/2015 - "A topical cocktail of strong steroid, NSAID, and carbonic anhydrase inhibitor drops are effective for managing cystoid macular edema. " 01/01/2015 - "To report the combination cocktail of strong steroid, non-steroidal anti-inflammatory drug (NSAID), and carbonic anhydrase inhibitor drops for treatment of cystoid macular edema. " 01/01/2015 - "Strong topical steroid, NSAID, and carbonic anhydrase inhibitor cocktail for treatment of cystoid macular edema." 01/01/2013 - "The purpose of this study was to evaluate prospectively the efficacy of a topical carbonic anhydrase inhibitor in macular edema after vitrectomy. " 01/01/2015 - "Focal photocoagulation interrupts vascular leakage in diabetic macular edema, and allows the retinal pigment epithelium to withdraw fluid that thickens the retina; this mechanism could be enhanced by dorzolamida, a topical carbonic anhydrase inhibitor. "
4.	Neoplasms (Cancer) 07/01/2013 - "To study the expression of carbonic anhydrase IX (CAIX), PAX2 and PAX8 in different types of renal epithelial tumor and their association with clinicopathologic characteristics. " 02/01/2011 - "Numerous studies over the past decade involving the cancer-specific carbonic anhydrase IX have re-kindled an interest in pH disruption-based therapies. " 03/01/2010 - "Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study." 04/01/2009 - "The carbonic anhydrase isoenzyme CA IX was selected for further studies due to its expression on the surface of many types of hypoxic tumors. " 11/01/2007 - "Carbonic anhydrase (CA) IX is a very interesting subject for study due to its overexpression in cancer and its expression in very few normal tissues. "
5.	Renal Cell Carcinoma (Grawitz Tumor) 05/01/2014 - "The PET tracer, (124)I-cG250, directed against carbonic anhydrase IX (CAIX) shows promise for presurgical diagnosis of clear-cell renal cell carcinoma (ccRCC) (Divgi et al. in Lancet Oncol 8:304-310, 2007; Divgi et al. in J Clin Oncol 31:187-194, 2013). " 04/01/2015 - "High expression of carbonic anhydrase IX (CA IX) has been reported in clear cell renal cell carcinoma (ccRCC); few studies have reported CA IX expression in other tumours with predominantly clear cell morphology. " 12/01/2014 - "In a clinical study in advanced renal cell carcinoma (RCC) patients with CAR T cells specific for carbonic anhydrase IX (CAIX), we observed toxicities that (most likely) indicated in vivo function of CAR T cells as well as low T cell persistence and clinical response rates. " 10/01/2012 - "This study aimed to evaluate the usefulness of carbonic anhydrase IX (CA-IX) expression in clear cell renal cell carcinoma (CCRCC) using two different techniques to detect protein expression. " 01/01/2012 - "High immunohistochemical expression of carbonic anhydrase IX (CAIX) is found in clear cell renal cell carcinoma (ccRCC), but no studies have assessed CAIX in metastatic ccRCC (mccRCC) of the lung. "

Related Drugs and Biologics

1.	Acetazolamide (Diamox)
2.	dorzolamide (Trusopt)
3.	Isoenzymes
4.	Protein Isoforms (Isoforms)
5.	Zinc
6.	Timolol (Blocadren)
7.	Carbon Monoxide
8.	Carbonic Anhydrase Inhibitors
9.	Interleukin-2 (IL2)
10.	Dichlorphenamide (Daranide)

Related Therapies and Procedures

1.	Radioimmunotherapy
2.	Intraperitoneal Injections
3.	Vitrectomy
4.	Off-Label Use
5.	Optical Devices